Drug Trial Radar · NCT02176876
Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Rheumatoid Arthritis
Last checked: Nov 20, 2026Latest source record: Jun 29, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Aug 2014
Primary completion
Apr 2015
Study completion Jun 2015
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Jun 27, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to assess the safety, tolerability, and pharmacokinetics (PK) of multiple infusions of GS-5745 in adults with rheumatoid arthritis (RA). Participants will be randomized in a 4:1 ratio to receive 1 intravenous (IV) infusion of GS-5745 or placebo every 2 weeks, for a total of 3 IV infusions.
Conditions
- Rheumatoid Arthritis
Interventions
GS-5745Drug
GS-5745 400 mg administered intravenously
Placebo to match GS-5745Drug
Placebo to match GS-5745 administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events, changes in laboratory tests and vital signs from baseline, and development of immunogenicity after dosingTime frame: Up to 100 days
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Prague, Czechia
Site not named
Budapest, Hungary
Site not named
Debrecen, Hungary
Site not named
Balatonfüred, Veszprém megye, Hungary
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.